Drugs / hTERT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01660529 | Jun 2012 → Nov 2015 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-11-27 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model inovio.com ↗
The combination therapies resulted in robust anti-tumor effects and showed significant improvement in survival compared to either therapy alone. |
| 2017-11-10 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗
Interim results presented at the conference show positive safety and tolerability data as well as the generation of hTERT-specific IFN-γ secreting T cells, suggestive of an ability to break immune tolerance. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-11-27 | Inovio Pharmaceuticals | Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model inovio.com ↗ |
| 2017-11-10 | Inovio Pharmaceuticals | Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hTERT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660529 ↗ |
| Modality | Vaccine | “hTERT/survivin/CMV multipeptide vaccine” NCT01660529 ↗ |
| Route | Subcutaneous | “subcutaneous vaccinations” NCT01660529 ↗ |